ClinicalTrials.gg
RecruitingNCT07287098preEMBERUpdated Nov 4, 2026

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

A Phase 2 interventional study of Imlunestrant and Goserelin in Breast Neoplasms, sponsored by Eli Lilly and Company. Recruiting at 90 sites in 7 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.
Updated Nov 4, 2026Site recruiting status changed3 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 88 studies in Breast Neoplasms by Eli Lilly and Company — 7 open to participants now, 22 under way, 8 of them phase 3. Breast Neoplasms · Eli Lilly and Company.

Planned enrollment
10th of 80
600 · median 138
Started
2026
with 1 other
Phase 2
41 of 88
2 open now
Primary completion
2029-01
later than 17 of 21 live
Registered
87th of 88
by date

Among the 88 studies in Breast Neoplasms by Eli Lilly and Company, this one is the 10th largest by planned enrollment of the 80 interventional ones that give a count, is one of 2 that started in 2026, is one of 41 in phase 2, reaches primary completion later than 17 of the 21 other live ones, and was the 87th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

7 of the 88 studies in Breast Neoplasms by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 88 studies in Breast Neoplasms by Eli Lilly and Company, or all of them as a file.
02

Study summary

This study will include two groups of patients: Cohort 1 and Cohort 2.

Cohort 1: will help researchers learn how a medicine called imlunestrant (LY3484356) affects a specific type of breast cancer. Some patients will take both imlunestrant and another treatment to suppress their ovarian function. Some will take it without ovarian suppression. Researchers will compare the effects in breast cancer cells to those of another medicine called tamoxifen. All patients in this group will be premenopausal women who have a type of early breast cancer called estrogen receptor-positive, HER2-negative. The treatment in this group will last for up to 29 days.

Cohort 2: will help researchers understand how imlunestrant affects the ovaries when it is taken without ovarian suppression. Researchers will compare the effects to those of another medicine called tamoxifen. This group will also include premenopausal women with the same type of breast cancer. The treatment in this group will last for up to 6 months.

03

Conditions studied

  • Breast Neoplasms

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Cohort 1:

  • Have confirmed Stage I to III Estrogen Receptor positive (ER+), human epidermal growth factor receptor 2 negative (-) invasive breast carcinoma with Ki-67 at least 10%
  • Be willing and able to provide pre- and on-treatment tumor samples.
  • Have an (ECOG) performance status of 0 or 1.
  • Be able to swallow capsules or tablets.
  • Be premenopausal women.
  • If of must use 1 highly effective method of non-hormonal while receiving study treatment and for the duration specified in protocol.
  • Have adequate organ function.

Cohort 2:

  • Have a diagnosis of ER+, HER2- early-stage, resected, invasive breast cancer without evidence of distant
  • Have undergone definitive loco-regional therapy.
  • Have received at least 4.5 years of any endocrine therapy (ET), or at least 2 years of adjuvant ET with no additional ovarian suppression planned.
  • Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Be able to swallow capsules or tablets.
  • Be premenopausal women
  • If of childbearing potential must use 1 highly effective method of non-hormonal contraception while receiving study treatment and for the duration specified in protocol.
  • Have adequate organ function.

Exclusion criteria

Exclusion Criteria:

Cohort 1:

  • Have bilateral invasive , occult primary, or inflammatory breast cancer.
  • Have had prior bilateral oophorectomy or ovarian ablation.
  • Have a serious medical condition
  • Had major surgery within 28 days prior to randomization.
  • Have a history of other cancer (except non melanoma skin cancer, Stage I uterine cancer, or carcinoma in situ of the cervix or other in situ cancer), unless in complete remission with no therapy for a minimum of 1 year.
  • Plan to receive concurrent therapy with any other non-protocol anticancer therapy.
  • Have had any prior therapy for an invasive or non-invasive breast cancer.
  • Have had prior radiotherapy to the ipsilateral chest wall for any .
  • Have received prior anti-estrogen therapy, including for osteoporosis or prevention of breast cancer.
  • Have had prior treatment with any Gonadotropin-releasing hormone (GnRH) agonist within 12 months prior to randomization.
  • Receiving current exogenous reproductive hormone therapy

Cohort 2:

  • Have ovarian cyst(s) greater than (>) 1 centimeter (cm) at screening.
  • Have metastatic occult primary, or inflammatory breast cancer.
  • Have had prior bilateral oophorectomy or ovarian ablation.
  • Have a serious medical condition
  • Had major surgery within 28 days prior to randomization.
  • Have a history of other cancer (except non melanoma skin cancer or carcinoma in situ of the cervix or other in situ cancer), unless in complete remission with no therapy for a minimum of 1 year.
  • Completed or discontinued prior adjuvant ET >6 months prior to screening.
  • Have received prior therapy with any selective estrogen receptor degrader (SERD).
  • Receiving current exogenous reproductive hormone therapy.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
600 participants (estimated)

Study arms

  • Experimental
    Cohort 1 Arm A

    Imlunestrant will be given orally

    Drug: Imlunestrant

  • Experimental
    Cohort 1 Arm B - Imlunestrant + Goserelin

    Imlunestrant will be given orally and goserelin will be given subcutaneously (SC)

    Drug: Imlunestrant · Drug: Goserelin

  • Active comparator
    Cohort 1 Arm C - Tamoxifen

    Tamoxifen will be given orally

    Drug: Tamoxifen 20 mg

  • Experimental
    Cohort 2 Arm A - Imlunestrant

    Imlunestrant will be given orally

    Drug: Imlunestrant

  • Active comparator
    Cohort 2 Arm B - Tamoxifen

    Tamoxifen will be given orally

    Drug: Tamoxifen 20 mg

Interventions

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Antigen Kiel (Ki-67) Expression

    Time frame: Baseline, Day 29

  2. Rate of Symptomatic Ovarian Cysts

    Time frame: Up to Day 180

Secondary outcomes

  1. Change from Baseline in Estrogen Receptor (ER) Expression

    Time frame: Baseline, Day 29

  2. Change from Baseline in Progesterone Receptor (PR) Expression

    Time frame: Baseline, Day 29

  3. Rate of Complex Ovarian Cysts

    Time frame: Up to Day 180

07

Study locations

25 of 90 sites recruiting
  • University of Alabama at Birmingham
    Birmingham, Alabama 35205, United States
    Not yet recruiting
    • Erica Stringer-Reasor · Principal investigator
  • Ironwood Cancer & Research Centers
    Chandler, Arizona 85224, United States
    Not yet recruiting
    • Sumeet Mendonca · Principal investigator
  • Mayo Clinic in Arizona - Phoenix
    Phoenix, Arizona 85054, United States
    Not yet recruiting
    • · Contact480-301-8000
    • Shakeela Bahadur · Principal investigator
  • City of Hope, Phoenix
    Phoenix, Arizona 85338, United States
    Not yet recruiting
    • Cynthia Lynch · Principal investigator
  • City of Hope
    Duarte, California 91010, United States
    Not yet recruiting
    • Hope Rugo · Principal investigator
  • City of Hope Orange County Lennar Foundation Cancer Center
    Irvine, California 92618, United States
    Not yet recruiting
    • Hope Rugo · Principal investigator
  • USC/Norris Comprehensive Cancer Center
    Los Angeles, California 90033, United States
    Recruiting
    • · Contact323-397-5954
    • Daphne Stewart · Principal investigator
  • UCLA Hematology/Oncology - Parkside
    Santa Monica, California 90404, United States
    Not yet recruiting
    • · Contact310-998-4747
    • Nicholas McAndrew · Principal investigator
  • Banner MD Anderson Cancer Center at North Colorado Medical Center
    Greeley, Colorado 80631, United States
    Recruiting
    • · Contact970-810-3894
    • Esther Mondo · Principal investigator
  • Banner MD Anderson Cancer Center at McKee Medical Center
    Loveland, Colorado 80538, United States
    Recruiting
    • · Contact970-810-3894
    • Esther Mondo · Principal investigator
  • AdventHealth Altamonte Springs
    Altamonte Springs, Florida 32701, United States
    Not yet recruiting
    • Wassim Mchayleh · Principal investigator
  • Mayo Clinic in Florida
    Jacksonville, Florida 32224, United States
    Not yet recruiting
    • · Contact904-953-2000
    • Rohit Rao · Principal investigator
  • Winship Cancer Institute
    Atlanta, Georgia 30322, United States
    Not yet recruiting
    • Manali Bhave · Principal investigator
  • City of Hope National Medical Center, Atlanta Cancer Center
    Newnan, Georgia 30265, United States
    Not yet recruiting
    • Sarah Friend · Principal investigator
  • City of Hope, Chicago
    Chicago, Illinois 60611, United States
    Not yet recruiting
    • Teja Poosarla · Principal investigator
  • Indiana University Melvin and Bren Simon Cancer Center
    Indianapolis, Indiana 46202, United States
    Recruiting
    • Rina Yadav · Principal investigator
  • University of Kentucky Chandler Medical Center
    Lexington, Kentucky 40536, United States
    Not yet recruiting
    • Ruta Arays · Principal investigator
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
    Not yet recruiting
    • · Contact617-726-6500
    • Seth Wander · Principal investigator
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
    Not yet recruiting
    • · Contact617-632-2335
    • Erica Mayer · Principal investigator
  • Mayo Clinic in Rochester, Minnesota
    Rochester, Minnesota 55905, United States
    Not yet recruiting
    • · Contact507-284-2511
    • Matthew Goetz · Principal investigator
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
    Not yet recruiting
    • Rebecca Aft · Principal investigator
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
    Not yet recruiting
    • Sherry Shen · Principal investigator
  • Wilmot Cancer Institute
    Rochester, New York 14642, United States
    Not yet recruiting
    • · Contact585-275-4823
    • Ajay Dhakal · Principal investigator
  • New York Cancer and Blood Specialists
    Shirley, New York 11967, United States
    Recruiting
    • · Contact631-675-5075
    • Richard Zuniga · Principal investigator
  • University of North Carolina Medical Center
    Chapel Hill, North Carolina 27514, United States
    Not yet recruiting
    • Jeffrey Aldrich · Principal investigator
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
    Suspended

    Not enrolling at this site — choose another above.

  • Providence Portland Medical Center
    Portland, Oregon 97213, United States
    Recruiting
    • · Contact503-215-5696
    • Alison Conlin · Principal investigator
  • Providence St. Vincent Medical Center
    Portland, Oregon 97225, United States
    Recruiting
    • · Contact503-215-5696
    • Alison Conlin · Principal investigator
  • Tennessee Oncology
    Nashville, Tennessee 37203, United States
    Recruiting
    • Sara Nunnery · Principal investigator
  • University of Texas MD Anderson Cancer Center
    Houston, Texas 77030-4009, United States
    Recruiting
    • · Contact832-728-7423
    • Taiwo Adesoye · Principal investigator
  • Houston Methodist Hospital
    Houston, Texas 77030, United States
    Not yet recruiting
    • Hanh Mai · Principal investigator
  • Oncology Consultants P.A.
    Houston, Texas 77030, United States
    Recruiting
    • · Contact713-600-0900
    • Ricardo Alvarez · Principal investigator
  • Baylor Scott & White Medical Center - Round Rock
    Round Rock, Texas 78665, United States
    Not yet recruiting
    • · Contact512-509-0200
    • Christal Murray · Principal investigator
  • Huntsman Cancer Institute
    Salt Lake City, Utah 84112, United States
    Not yet recruiting
    • · Contact801-585-0236
    • Jairam Krishnamurthy · Principal investigator
  • The University of Vermont Medical Center Inc.
    Burlington, Vermont 05401, United States
    Not yet recruiting
    • Peter Kaufman · Principal investigator
  • University of Virginia Health System
    Charlottesville, Virginia 22903, United States
    Recruiting
    • · Contact434-924-9333
    • Trish Millard · Principal investigator
  • Inova Schar Cancer Institute
    Fairfax, Virginia 22031, United States
    Recruiting
    • Jennifer Matro · Principal investigator
  • Cliniques universitaires Saint-Luc
    Brussels, 1200, Belgium
    Not yet recruiting
    • · Contact3227645435
    • Francois Duhoux · Principal investigator
  • Antwerp University Hospital
    Edegem, 2650, Belgium
    Not yet recruiting
    • Sevilay Altintas · Principal investigator
  • UZ Leuven
    Leuven, 3000, Belgium
    Not yet recruiting
    • · Contact003216345129
    • Patrick Neven · Principal investigator
  • CHRU de Brest
    Brest, 29609, France
    Recruiting
    • Laura Deiana · Principal investigator
  • Centre de Cancérologie du Grand Montpellier
    Montpellier, 34070, France
    Recruiting
    • · Contact467926155
    • Cristian Villanueva · Principal investigator
  • Hôpital Privé Des Côtes d'Armor
    Plérin, 22190, France
    Recruiting
    • Jerome Martin-Babau · Principal investigator
  • Institut Curie - site Saint-Cloud
    Saint-Cloud, 92210, France
    Recruiting
    • Diana Bello Roufai · Principal investigator
  • Gustave Roussy
    Villejuif, 94800, France
    Not yet recruiting
    • Barbara Pistilli · Principal investigator
  • Evangelisches Krankenhaus Bergisch Gladbach
    Bergisch Gladbach, 51465, Germany
    Not yet recruiting
    • Christian Rudlowski · Principal investigator
  • Praxis am Volkspark
    Berlin, 10715, Germany
    Not yet recruiting
    • Jan-Piet Habbel · Principal investigator
  • Onkologische Schwerpunktpraxis Bielefeld
    Bielefeld, 33604, Germany
    Recruiting
    • Siemke Steinke · Principal investigator
  • Augusta-Kranken-Anstalt
    Bochum, 44791, Germany
    Not yet recruiting
    • Matthias Losch · Principal investigator
  • Gynaekologisches Zentrum Bonn
    Bonn, 53111, Germany
    Not yet recruiting
    • · Contact004922890927671
    • Christian Kurbacher · Principal investigator
  • Marienhospital Bottrop
    Bottrop, 46236, Germany
    Not yet recruiting
    • · Contact4920411061601
    • Hans-Christian Kolberg · Principal investigator
  • Onkologisch - Hämatologische Schwerpunktpraxis
    Bremen, 28209, Germany
    Not yet recruiting
    • Ralf Meyer · Principal investigator
  • Medizinische Universität Lausitz- Carl Thiem
    Cottbus, 03048, Germany
    Suspended

    Not enrolling at this site — choose another above.

  • Gemeinschaftspraxis Hämatologie - Onkologie Freiberg-Richter, Jacobasch, Illmer, Wolf
    Dresden, 01307, Germany
    Not yet recruiting
    • Thomas Illmer · Principal investigator
  • Universitaetsklinikum Erlangen
    Erlangen, 91054, Germany
    Recruiting
    • · Contact+4991318533572
    • Peter Fasching · Principal investigator
  • Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung
    Essen, 45136, Germany
    Not yet recruiting
    • · Contact+4920117433005
    • Sherko Kümmel · Principal investigator
  • Universitaetsklinikum Essen
    Essen, 45147, Germany
    Not yet recruiting
    • Ann-Kathrin Bittner · Principal investigator
  • Agaplesion Markus Krankenhaus
    Frankfurt, 60431, Germany
    Not yet recruiting
    • · Contact00496995332228
    • Marc Thill · Principal investigator
  • Mammazentrum HH - Krankenhaus Jerusalem
    Hamburg, 20357, Germany
    Not yet recruiting
    • · Contact00494044190670
    • Anne-Sophie Adam · Principal investigator
  • Praxisklinik Harburg
    Hamburg, 21073, Germany
    Not yet recruiting
    • · Contact0049 40 303 754 25
    • Christoph Grossmann · Principal investigator
  • Frauenärzte am Bahnhofsplatz
    Hildesheim, 31134, Germany
    Recruiting
    • · Contact+49 (5121) 59 02 - 0
    • Christoph Uleer · Principal investigator
  • Universitaetsklinikum Schleswig-Holstein Campus Kiel
    Kiel, 24105, Germany
    Not yet recruiting
    • · Contact+4943150021686
    • Marion van Mackelenbergh · Principal investigator
  • Evangelisches Krankenhaus Bethesda Mönchengladbach
    Mönchengladbach, 41061, Germany
    Recruiting
    • Katja Krauss · Principal investigator
  • Klinikum der Ludwig-Maximilians-Universitaet Muenchen
    München, 80336, Germany
    Not yet recruiting
    • · Contact004989440077581
    • Nadia Harbeck · Principal investigator
  • Rotkreuzklinikum München gemeinnützige GmbH
    München, 80637, Germany
    Recruiting
    • · Contact00498913033797
    • Michael Braun · Principal investigator
  • Ruppiner Kliniken
    Neuruppin, 16816, Germany
    Not yet recruiting
    • Verena Kiver · Principal investigator
  • Klinikum Ernst von Bergmann
    Potsdam, 14467, Germany
    Not yet recruiting
    • · Contact+4933124135643
    • Dorothea Fischer · Principal investigator
  • MVZ für Hämatologie und Onkologie Ravensburg GmbH - Studienzentrum
    Ravensburg, 88212, Germany
    Not yet recruiting
    • Thomas Decker · Principal investigator
  • Klinikum Mutterhaus der Borromäerinnen
    Trier, 54290, Germany
    Recruiting
    • Sebastian Jud · Principal investigator
  • Universitaetsklinikum Tuebingen
    Tübingen, 72076, Germany
    Not yet recruiting
    • · Contact004970712982211
    • Tobias Engler · Principal investigator
  • Universitaetsklinikum Ulm
    Ulm, 89075, Germany
    Not yet recruiting
    • · Contact004973150058531
    • Henning Schäffler · Principal investigator
  • Klinik Weinheim
    Weinheim, 69469, Germany
    Not yet recruiting
    • Lelia Bauer · Principal investigator
  • Helios HSK Wiesbaden
    Wiesbaden, 65199, Germany
    Not yet recruiting
    • · Contact0049611432377
    • Michael Eichbaum · Principal investigator
  • Marien Hospital Witten
    Witten, 58452, Germany
    Not yet recruiting
    • · Contact004923021733290
    • Monika Graeser · Principal investigator
  • HELIOS Klinikum Wuppertal
    Wuppertal, 42283, Germany
    Not yet recruiting
    • · Contact0492028961411
    • Vesna Bjelic-Radisic · Principal investigator
  • St. Vincent's University Hospital
    Dublin, D04 T6F4, Ireland
    Not yet recruiting
    • · Contact012214000
    • Janice Walshe · Principal investigator
  • St. James's Hospital
    Dublin, D08 E9P6, Ireland
    Not yet recruiting
    • · Contact014103000
    • Ciara O Hanlon Brown · Principal investigator
  • Galway University Hospital
    Galway, H91 YR71, Ireland
    Not yet recruiting
    • Maccon Keane · Principal investigator
  • Ente Ospedaliero Ospedali Galliera
    Genova, 16128, Italy
    Recruiting
    • · Contact+39.010563.4580
    • Matteo Lambertini · Principal investigator
  • Humanitas
    Milan, 20089, Italy
    Not yet recruiting
    • · Contact0039028224 4089
    • carmen criscitiello · Principal investigator
  • Istituto Europeo di Oncologia IRCCS
    Milan, 20141, Italy
    Not yet recruiting
    • · Contact00390257489215
    • Giuseppe Curigliano · Principal investigator
  • Humanitas Istituto Clinico Catanese
    Misterbianco, 95045, Italy
    Recruiting
    • Maria Vita Sanò · Principal investigator
  • Nuovo Ospedale di Prato-S.Stefano
    Prato, 59100, Italy
    Recruiting
    • · Contact+39 0574 802531
    • Laura Biganzoli · Principal investigator
  • Fondazione Policlinico Universitario Agostino Gemelli
    Roma, 00168, Italy
    Not yet recruiting
    • · Contact00390630157337
    • Alessandra Fabi · Principal investigator
  • Kaohsiung Medical University Chung-Ho Memorial Hospital
    Kaohsiung City, 807, Taiwan
    Not yet recruiting
    • · Contact8867-3121101 ext.6235
    • Ming-Feng Hou · Principal investigator
  • China Medical University Hospital
    Taichung, 404332, Taiwan
    Not yet recruiting
    • Hwei-Chung Wang · Principal investigator
  • Taichung Veterans General Hospital
    Taichung, 407, Taiwan
    Not yet recruiting
    • · Contact886-42359-2525-5031
    • Chih-Chiang Hung · Principal investigator
  • National Cheng Kung University Hospital
    Tainan, 704, Taiwan
    Not yet recruiting
    • Kuo-Ting Lee · Principal investigator
  • Mackay Memorial Hospital
    Taipei, 10449, Taiwan
    Not yet recruiting
    • · Contact886975835311
    • Yuan-Ching Chang · Principal investigator
  • Chang Gung Medical Foundation-Linkou Branch
    Taoyuan, 333, Taiwan
    Not yet recruiting
    • Shih-Che Shen · Principal investigator
08

References and documents

Related links

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication or approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal should be approved by an independent review panel and researchers should sign a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Jan 2029, 32 months after the start.

Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's planned 32 months is close to that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2025
First posted
Dec 17, 2025
StartActual
May 13, 2026
Primary completionEst.
Jan 2029
CompletionEst.
Dec 2029
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added, 1 site removed. 17 sites changed recruiting status (15 now recruiting, 1 now not yet recruiting, …)
Show 17 sites
  • Ironwood Cancer & Research Centers · Chandler, United StatesSuspended→Not yet recruiting
  • Inova Schar Cancer Institute · Fairfax, United StatesNot yet recruiting→Recruiting
  • Evangelisches Krankenhaus Bethesda Mönchengladbach · Mönchengladbach, GermanyNot yet recruiting→Recruiting
  • Nuovo Ospedale di Prato-S.Stefano · Prato, ItalyNot yet recruiting→Recruiting
  • USC/Norris Comprehensive Cancer Center · Los Angeles, United StatesNot yet recruiting→Recruiting
  • Banner MD Anderson Cancer Center at North Colorado Medical Center · Greeley, United StatesNot yet recruiting→Recruiting
  • Banner MD Anderson Cancer Center at McKee Medical Center · Loveland, United StatesNot yet recruiting→Recruiting
  • Providence Portland Medical Center · Portland, United StatesNot yet recruiting→Recruiting
  • Providence St. Vincent Medical Center · Portland, United StatesNot yet recruiting→Recruiting
  • University of Virginia Health System · Charlottesville, United StatesNot yet recruiting→Recruiting
  • Hôpital Privé Des Côtes d'Armor · Plérin, FranceNot yet recruiting→Recruiting
  • Institut Curie - site Saint-Cloud · Saint-Cloud, FranceNot yet recruiting→Recruiting
  • Medizinische Universität Lausitz- Carl Thiem · Cottbus, GermanyNot yet recruiting→Suspended
  • Universitaetsklinikum Erlangen · Erlangen, GermanyNot yet recruiting→Recruiting
  • Rotkreuzklinikum München gemeinnützige GmbH · München, GermanyNot yet recruiting→Recruiting
  • Ente Ospedaliero Ospedali Galliera · Genova, ItalyNot yet recruiting→Recruiting
  • Humanitas Istituto Clinico Catanese · Misterbianco, ItalyNot yet recruiting→Recruiting
Show 3 added (3 United States)
  • City of Hope, Phoenix · Phoenix, United States
  • City of Hope National Medical Center, Atlanta Cancer Center · Newnan, United States
  • City of Hope, Chicago · Chicago, United States
Show 1 removed
  • Studien GbR Braunschweig · Braunschweig, Germany
across 2 updates, Oct 8, 2026 – Nov 4, 2026
Site contacts
Changed at 2 sites. See the sites
Show 2 sites
  • Ironwood Cancer & Research Centers · Chandler, United StatesContact added (no phone or email listed)
  • Medizinische Universität Lausitz- Carl Thiem · Cottbus, GermanyContact removed (no phone or email listed)
across 2 updates, Oct 8, 2026 – Nov 4, 2026
Show all 2 updates
  1. Nov 4, 2026
    3 sites added. 13 sites changed recruiting status (12 now recruiting, 1 now suspended)
    Show 13 sites
    • USC/Norris Comprehensive Cancer Center · Los Angeles, United StatesNot yet recruiting→Recruiting
    • Banner MD Anderson Cancer Center at North Colorado Medical Center · Greeley, United StatesNot yet recruiting→Recruiting
    • Banner MD Anderson Cancer Center at McKee Medical Center · Loveland, United StatesNot yet recruiting→Recruiting
    • Providence Portland Medical Center · Portland, United StatesNot yet recruiting→Recruiting
    • Providence St. Vincent Medical Center · Portland, United StatesNot yet recruiting→Recruiting
    • University of Virginia Health System · Charlottesville, United StatesNot yet recruiting→Recruiting
    • Hôpital Privé Des Côtes d'Armor · Plérin, FranceNot yet recruiting→Recruiting
    • Institut Curie - site Saint-Cloud · Saint-Cloud, FranceNot yet recruiting→Recruiting
    • Medizinische Universität Lausitz- Carl Thiem · Cottbus, GermanyNot yet recruiting→Suspended
    • Universitaetsklinikum Erlangen · Erlangen, GermanyNot yet recruiting→Recruiting
    • Rotkreuzklinikum München gemeinnützige GmbH · München, GermanyNot yet recruiting→Recruiting
    • Ente Ospedaliero Ospedali Galliera · Genova, ItalyNot yet recruiting→Recruiting
    • Humanitas Istituto Clinico Catanese · Misterbianco, ItalyNot yet recruiting→Recruiting
    Show 3 added (3 United States)
    • City of Hope, Phoenix · Phoenix, United States
    • City of Hope National Medical Center, Atlanta Cancer Center · Newnan, United States
    • City of Hope, Chicago · Chicago, United States
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Medizinische Universität Lausitz- Carl Thiem · Cottbus, GermanyContact removed (no phone or email listed)
    + 1 other change: verification date
  2. Oct 8, 2026
    1 site removed. 4 sites changed recruiting status (3 now recruiting, 1 now not yet recruiting)
    Show 4 sites
    • Ironwood Cancer & Research Centers · Chandler, United StatesSuspended→Not yet recruiting
    • Inova Schar Cancer Institute · Fairfax, United StatesNot yet recruiting→Recruiting
    • Evangelisches Krankenhaus Bethesda Mönchengladbach · Mönchengladbach, GermanyNot yet recruiting→Recruiting
    • Nuovo Ospedale di Prato-S.Stefano · Prato, ItalyNot yet recruiting→Recruiting
    Show 1 removed
    • Studien GbR Braunschweig · Braunschweig, Germany
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Ironwood Cancer & Research Centers · Chandler, United StatesContact added (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07287098
Responsible party
Sponsor
First posted
Dec 17, 2025
Start date
May 13, 2026
Primary completion
Jan 2029 (estimated)
Completion
Dec 2029 (estimated)
Last update
Nov 4, 2026

Study contacts

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Contact
LillyTrials@Lilly.com
1-317-615-4559
Physicians interested in becoming principal investigators please contact
Contact
clinical_inquiry_hub@lilly.com
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Imlunestrant

Start the discussion